Sinopharm Group Co. Ltd. (SHTDY)
USD 11.35
(1.25%)
USD 11.35
(1.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.97 Billion CNY | -30.59% |
| 2022 | 14.36 Billion CNY | -42.15% |
| 2021 | 24.83 Billion CNY | 35.37% |
| 2020 | 18.34 Billion CNY | 15.06% |
| 2019 | 15.94 Billion CNY | 7.71% |
| 2018 | 14.8 Billion CNY | 121.75% |
| 2017 | 6.67 Billion CNY | -15.75% |
| 2016 | 7.92 Billion CNY | -10.88% |
| 2015 | 8.89 Billion CNY | -37.47% |
| 2014 | 14.22 Billion CNY | 27.68% |
| 2013 | 11.13 Billion CNY | 75.21% |
| 2012 | 6.35 Billion CNY | 738.62% |
| 2011 | 758.12 Million CNY | 118.77% |
| 2010 | -4.03 Billion CNY | 27.9% |
| 2009 | -5.6 Billion CNY | -7087.94% |
| 2008 | -77.94 Million CNY | -121.43% |
| 2007 | 363.72 Million CNY | 740.5% |
| 2006 | 43.27 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 52.28 Billion CNY | 103.6% |
| 2024 Q1 | 28.35 Billion CNY | 184.27% |
| 2023 Q3 | 44.5 Billion CNY | -26.38% |
| 2023 FY | 9.97 Billion CNY | -30.59% |
| 2023 Q4 | 9.97 Billion CNY | -77.59% |
| 2023 Q2 | 60.45 Billion CNY | 136.02% |
| 2023 Q1 | 25.61 Billion CNY | 78.27% |
| 2022 Q2 | 59.75 Billion CNY | 31.75% |
| 2022 FY | 14.36 Billion CNY | -42.15% |
| 2022 Q3 | 37.79 Billion CNY | -36.76% |
| 2022 Q4 | 14.36 Billion CNY | -61.98% |
| 2022 Q1 | 45.35 Billion CNY | 82.6% |
| 2021 Q4 | 24.83 Billion CNY | -43.85% |
| 2021 Q1 | 52.85 Billion CNY | 188.03% |
| 2021 Q3 | 44.23 Billion CNY | -15.63% |
| 2021 FY | 24.83 Billion CNY | 35.37% |
| 2021 Q2 | 52.42 Billion CNY | -0.8% |
| 2020 Q3 | 30.67 Billion CNY | -37.29% |
| 2020 Q2 | 48.9 Billion CNY | 201.98% |
| 2020 Q1 | 16.19 Billion CNY | 1.56% |
| 2020 FY | 18.34 Billion CNY | 15.06% |
| 2020 Q4 | 18.34 Billion CNY | -40.18% |
| 2019 Q1 | 6.54 Billion CNY | -55.78% |
| 2019 Q2 | 40.3 Billion CNY | 515.71% |
| 2019 Q3 | 15.72 Billion CNY | -60.98% |
| 2019 Q4 | 15.94 Billion CNY | 1.41% |
| 2019 FY | 15.94 Billion CNY | 7.71% |
| 2018 Q2 | 24.73 Billion CNY | -27.37% |
| 2018 Q1 | 34.05 Billion CNY | 410.14% |
| 2018 FY | 14.8 Billion CNY | 121.75% |
| 2018 Q4 | 14.8 Billion CNY | 0.0% |
| 2017 Q3 | 5 Billion CNY | -78.51% |
| 2017 Q4 | 6.67 Billion CNY | 33.47% |
| 2017 FY | 6.67 Billion CNY | -15.75% |
| 2017 Q2 | 23.27 Billion CNY | 0.0% |
| 2017 Q1 | 23.27 Billion CNY | 193.71% |
| 2016 Q1 | 21.14 Billion CNY | 137.8% |
| 2016 Q4 | 7.92 Billion CNY | 0.0% |
| 2016 Q3 | 7.92 Billion CNY | -25.41% |
| 2016 Q2 | 10.62 Billion CNY | -49.76% |
| 2016 FY | 7.92 Billion CNY | -10.88% |
| 2015 Q1 | 16.42 Billion CNY | 15.47% |
| 2015 FY | 8.89 Billion CNY | -37.47% |
| 2015 Q3 | 8.99 Billion CNY | -48.92% |
| 2015 Q2 | 17.61 Billion CNY | 7.26% |
| 2015 Q4 | 8.89 Billion CNY | -1.16% |
| 2014 Q1 | 13.99 Billion CNY | 25.67% |
| 2014 Q4 | 14.22 Billion CNY | 0.0% |
| 2014 FY | 14.22 Billion CNY | 27.68% |
| 2014 Q3 | 14.22 Billion CNY | 1.6% |
| 2014 Q2 | 13.99 Billion CNY | 0.0% |
| 2013 Q2 | 8.15 Billion CNY | 0.0% |
| 2013 Q1 | 8.15 Billion CNY | 28.25% |
| 2013 FY | 11.13 Billion CNY | 75.21% |
| 2013 Q4 | 11.13 Billion CNY | 0.0% |
| 2013 Q3 | 11.13 Billion CNY | 36.61% |
| 2012 FY | 6.35 Billion CNY | 738.62% |
| 2012 Q2 | 2.7 Billion CNY | 0.0% |
| 2012 Q4 | 6.35 Billion CNY | 0.0% |
| 2011 FY | 758.12 Million CNY | 118.77% |
| 2011 Q4 | 758.12 Million CNY | 0.0% |
| 2011 Q2 | -3.13 Billion CNY | 0.0% |
| 2010 FY | -4.03 Billion CNY | 27.9% |
| 2010 Q4 | -4.03 Billion CNY | 0.0% |
| 2010 Q2 | -6.22 Billion CNY | 0.0% |
| 2009 FY | -5.6 Billion CNY | -7087.94% |
| 2009 Q4 | -5.6 Billion CNY | 0.0% |
| 2009 Q2 | -128.23 Million CNY | 0.0% |
| 2008 Q4 | -77.94 Million CNY | 0.0% |
| 2008 FY | -77.94 Million CNY | -121.43% |
| 2007 FY | 363.72 Million CNY | 740.5% |
| 2006 FY | 43.27 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| China Medicine Corporation | 9.03 Million USD | -110292.765% |
| DH Enchantment Inc. | 409.44 Thousand USD | -2435712.869% |
| Exlites Holdings International, Inc. | - USD | -Infinity% |
| Itonis, Inc. | 909.99 Thousand USD | -1095870.98% |
| One Step Vending Corp. | 247.1 Thousand USD | -4035914.212% |
| MediPal Holdings Corporation | -1.49 Billion USD | 766.073% |
| PD-Rx Pharmaceuticals, Inc. | -6.83 Million USD | 146047.035% |
| Pharmagen, Inc. | 4362.26 USD | -228627125.337% |
| Suzuken Co., Ltd. | -1.17 Billion USD | 948.309% |